All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma Hub

Brought to you by Scientific Education Support

Scientific Education Support

The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My Lymphoma Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View lymphoma & CLL content recommended for you

ESMO 2022

Share:

Sep 12, 2022

X post image

12 Sept 2022

#ESMO22│@drclaireroddie from @uclcancer @UCLH offers further expertise on toxicities with #CART and #bispecifics, including management of ICANS and stratification of cytopenia risk and management #mmsm #lymphoma #scientificcongress

X post image

12 Sept 2022

#ESMO22│@drclaireroddie from @uclcancer @UCLH gives her expert opinion on toxicities with #CART and #bispecifics, including potential for dasatinib to manage CRS, and the strong association of HLH with CD22 #CART #mmsm #lymphoma

X post image

12 Sept 2022

CONGRESS | #ESMO22 | Poster
Patrick Connor Johnson @MGH_CCCSEW presented results from a real-world analysis comparing QoL by region (Western Europe & the US) and by the line of therapy in patients with follicular lymphoma. N=401
#lymphoma #lymsm

X post image

12 Sept 2022

CONGRESS | #ESMO22 | Poster
Adolfo de la Fuente Burguera @MDAnderson_ES presented a phase II trial design of glucarpidase in patients with R/R DLBCL at high risk of CNS relapse
#lymphoma #lymsm

X post image

12 Sept 2022

CONGRESS | #ESMO22 | Poster
@DrMatasar @MSKCancerCenter presented VITALIZE phase IIb trial design of maveropepimut-S, pembrolizumab±intermittent low-dose cyclophosphamide in R/R DLBCL. The study will enroll up to 102 eligible subjects at 65 global study sites
#lymphoma #lymsm

X post image

12 Sept 2022

CONGRESS #ESMO22 | Irit Avivi presented data on behalf of T. Guan, Shanxi Provincial Cancer Hospital, on ctDNA as a prognostic factor & tumor-specific biomarker for DLBCL in China. High levels of ctDNA (>23%) were associated with inferior OS & PFS #lymsm #lymphoma

X post image

12 Sept 2022

CONGRESS #ESMO22 | Charlotte Syrykh @IUCTOncopole presented a machine learning-based prediction of DLBCL subtypes using whole slide images. Predictions of DPE status, MYC rearrangements (P<0.001) & MUM1 expression were associated with worse overall survival #lymsm #lymphoma

X post image

12 Sept 2022

CONGRESS #ESMO22 | Yunhong Huang at Guizhou Medical University presented results from phase I/II trial of PLM60+pegaspargase in pts with extranodal NK/T-cell lymphoma. N=22 (treatment-naïve pts), CR: 68.2%, ORR: 90.9%, Median PFS: not reached, safety: manageable #lymsm #lymphoma

X post image

12 Sept 2022

CONGRESS #ESMO22 | Mingyue Wang at Guangxi Medical University presented outcomes of orelabrutinib+RCHOP in previously untreated non-GCB DLBCL patients with extranodal disease.
Median follow-up: 11 months, ORR: 86.4%, PD: 13.6%, median PFS: not reached #lymsm #lymphoma

X post image

12 Sept 2022

CONGRESS #ESMO22 | Haiying Wang at Hrain Biotechnology Co Ltd presented efficacy results of DASH CAR T-cells manufactured in 2 days. DASH CAR T-cells expanded significantly better in vivo and were more effective than conventional #CAR T-cells #lymsm #lymphoma

X post image

12 Sept 2022

CONGRESS #ESMO22 | Martin @DocHutchings @rigshospitalet discussed newly approved drugs and future therapeutic strategies in early diffuse large B-cell lymphoma #lymsm #lymphoma

X post image

12 Sept 2022

CONGRESS #ESMO22 | Marco Ladetto @UniAvogadro discussed the novel treatment approaches (BTKi, CAR-T and combination therapy) and future perspective to treat early relapse in mantle cell lymphoma #lymsm #lymphoma

X post image

12 Sept 2022

CONGRESS #ESMO22 | Catherine Thieblemont @HopSaintLouis presented novel therapeutic approaches including combination chemo-free therapies and T-cell engagers in early follicular lymphoma #lymsm #lymphoma

X post image

12 Sept 2022

It’s Day 4 of #ESMO22!

The following sessions will be covered today:

– Emerging Toxicities of New Anticancer Therapies
– Hematological Malignancies
– How to Treat Early Relapses in FL, MCL, DLBCL

Keep an eye on our Twitter page for live updates!
#medicalcongress

X post image

11 Sept 2022

#ESMO22│Andres Ferreri from @SanRaffaeleMI discusses considerations in the diagnosis, staging, primary and salvage therapies, clinical outcomes and the future of care in primary CNS #lymphoma #lymsm

X post image

11 Sept 2022

#ESMO22│Andres Ferreri from @SanRaffaeleMI discusses a case presentation by Daniela Alves on a challenging patient with primary CNS disease #lymphoma, with treatment with MATRix chemotherapy

X post image

11 Sept 2022

It’s Day 3 of #ESMO22!

The following sessions will be covered today:

– ESMO clinical practice guidelines on primary CNS lymphoma
– What is the optimal first-line therapy for CLL?

Keep an eye on our Twitter page for live updates!

#medicalcongress
#cancerawareness

X post image

11 Sept 2022

#ESMO22│ Clemens-Martin Wendtner from @muenchenklinik continues his expert opinion on the first line treatment for #CLL including further trial data and use of anti-CD20 in TP53 frail patients #leusm #medicalcongress

X post image

11 Sept 2022

#ESMO22│ Clemens-Martin Wendtner from @muenchenklinik presents his expert opinion on the first line treatment of #CLL, including latest clinical trial data, toxicities with #BTKi, when to use obinutuzumab as choice of anti-CD20 and novel #CLL guidelines #leusm #medicalcongress

X post image

11 Sept 2022

CONGRESS | #ESMO22 | Hong Cen at Guangxi Medical University presents data from a study of shRNA-mediated PD1 gene knock-down anti-CD19 CAR-T cell therapy in pts with R/R B-cell malignancies
ORR was 62.5% and PD was 37.5% with an acceptable safety profile.
#lymphoma #lymsm

X post image

10 Sept 2022

CONGRESS | #ESMO22 | Poster
Olufunmilayo Bamigbola at Lymphoma Coalition presented results from a comparative study to evaluate the impact of countries’ health expenditure (%GDP) on the support experiences of patients with lymphoma & CLL in Europe (N=4,346).
#lymphoma #lymsm

X post image

10 Sept 2022

#ESMO22│Marius Mayerhoefer from @MSKCancerCenter explains the use of novel #PET techniques in haematological malignancy, including #CLL, #myeloma and lymphoplasmacytic lymphoma #lymphoma #lymsm #myeloma #mmsm #medicalcongress

X post image

10 Sept 2022

#ESMO22│Marius Mayerhoerfer from @MSKCancerCenter discusses new #PET techniques in haematological malignancies, and their applications in diagnosis and treatment #lymphoma #lymsm #myeloma #mmsm #medicalcongress

X post image

10 Sept 2022

CONGRESS | #ESMO22 | Yuan-Kai Shi at the Chinese Academy of Medical Sciences presents data from a phase I trial of TRS005 in pts with R/R B-cell #NHL.
N=48; TRS005 showed a favorable efficacy (ORR:42.2%, DCR:75.6%, mPFS:4 months) and a manageable safety profile. #lymphoma #lymsm

X post image

10 Sept 2022

The @lymphomahub continues to bring you comprehensive updates from #ESMO22 as we continue our live coverage!

The following session will be covered today:

Proffered Paper Session on Hematological Malignancies

#medicalcongress
#cancerawareness

X post image

9 Sept 2022

#ESMO22│Fabrice Jardin from @CentreBecquerel discusses advances in the molecular classification of aggressive and high grade #lymphoma, including MYC-rearrangement, activated B-cell and germinal-cell disease #lymsm #medicalcongress

X post image

9 Sept 2022

#ESMO22│@FSchererMD from @Uniklinik_Fr discusses how circulating tumour cells can be used in the diagnosis, tumour genotyping and identification of refractory disease in #lymphoma subtypes, including #DLBCL and primary CNS lymphoma #ctDNA #lymsm

X post image

9 Sept 2022

#ESMO22│@FSchererMD from @Uniklinik_Fr
presents the latest research on the use of circulating tumour cells in the diagnosis, monitoring and management #lymphoma #medicalcongress #ctDNA #lymsm

X post image

9 Sept 2022

#ESMO22 starts today!

The @lymphomahub will be virtually covering the following session:

How Diagnostic Tools Impact Therapy of Hematological Malignancies

#medicalcongress #cancerawareness

X post image

8 Sept 2022

The @lymphomahub will be virtually covering #ESMO22, providing you with live updates, key insights, and interview coverage!

Dates: September 9–13
Location: Paris, France & Online

Keep an eye on our Twitter page!

@myESMO

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.

Your opinion matters

When selecting the next therapy for patients with R/R MCL after BTKi progression, what is your most important consideration?

Newsletter

Subscribe to get the best content delivered to your inbox